Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma

Hirokazu Miyatake, Yoshiyuki Kobayashi, Yoshiaki Iwasaki, Shin Ichiro Nakamura, Hideki Ohnishi, Kenji Kuwaki, Junichi Toshimori, Hiroaki Hagihara, Kazuhiro Nouso, Kazuhide Yamamoto

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background and Aims Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) prevents the development of hepatocellular carcinoma (HCC). The purpose of this study was to clarify the effect of previous IFN treatment before the development of HCC on recurrence and survival in HCV-related HCC patients. Methods Three hundred ninety-five patients who underwent curative treatment for HCV-related HCC were enrolled. Of these, 124 hadReceived IFN treatment before the development of HCC (17 achieved sustained virological response [SVR group] and 107 did not [non-SVR group]), whereas 271 patients had never Received IFN treatment (IFN-untreated group). The first and second recurrence and survival rates in these patient groups were statistically analyzed. Results The first HCC recurrence rate was similar among patient groups. In contrast, the second HCC recurrence rate was significantly lower in the SVR group than in the non- SVR group (p = 0.003) and the IFN-untreated group (p = 0.006). In multivariate analysis, platelet count (p = 0.033) and number of tumors (p = 0.001) were associated with the first HCC recurrence, while SVR (p = 0.002) was the only factor associated with the second HCC recurrence. The survival rate was higher in the SVR group than in non-SVR and IFN-untreated groups, and SVR to previous IFN treatment was an independent factor associated with better survival (p\0.001). Conclusions SVR to previous IFN treatment before the development of HCV-related HCC was associated with lower risk of the second recurrence of HCC and better survival.

Original languageEnglish
Pages (from-to)1092-1101
Number of pages10
JournalDigestive Diseases and Sciences
Volume57
Issue number4
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Hepacivirus
Interferons
Hepatocellular Carcinoma
Recurrence
Therapeutics
Survival
Survival Rate
Chronic Hepatitis C
Virus Diseases
Platelet Count
Multivariate Analysis

Keywords

  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Previous interferon therapy
  • Recurrence
  • Survival

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. / Miyatake, Hirokazu; Kobayashi, Yoshiyuki; Iwasaki, Yoshiaki; Nakamura, Shin Ichiro; Ohnishi, Hideki; Kuwaki, Kenji; Toshimori, Junichi; Hagihara, Hiroaki; Nouso, Kazuhiro; Yamamoto, Kazuhide.

In: Digestive Diseases and Sciences, Vol. 57, No. 4, 04.2012, p. 1092-1101.

Research output: Contribution to journalArticle

Miyatake, Hirokazu ; Kobayashi, Yoshiyuki ; Iwasaki, Yoshiaki ; Nakamura, Shin Ichiro ; Ohnishi, Hideki ; Kuwaki, Kenji ; Toshimori, Junichi ; Hagihara, Hiroaki ; Nouso, Kazuhiro ; Yamamoto, Kazuhide. / Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. In: Digestive Diseases and Sciences. 2012 ; Vol. 57, No. 4. pp. 1092-1101.
@article{da125c8cd4db4862a0bd1a3409811f7c,
title = "Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma",
abstract = "Background and Aims Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) prevents the development of hepatocellular carcinoma (HCC). The purpose of this study was to clarify the effect of previous IFN treatment before the development of HCC on recurrence and survival in HCV-related HCC patients. Methods Three hundred ninety-five patients who underwent curative treatment for HCV-related HCC were enrolled. Of these, 124 hadReceived IFN treatment before the development of HCC (17 achieved sustained virological response [SVR group] and 107 did not [non-SVR group]), whereas 271 patients had never Received IFN treatment (IFN-untreated group). The first and second recurrence and survival rates in these patient groups were statistically analyzed. Results The first HCC recurrence rate was similar among patient groups. In contrast, the second HCC recurrence rate was significantly lower in the SVR group than in the non- SVR group (p = 0.003) and the IFN-untreated group (p = 0.006). In multivariate analysis, platelet count (p = 0.033) and number of tumors (p = 0.001) were associated with the first HCC recurrence, while SVR (p = 0.002) was the only factor associated with the second HCC recurrence. The survival rate was higher in the SVR group than in non-SVR and IFN-untreated groups, and SVR to previous IFN treatment was an independent factor associated with better survival (p\0.001). Conclusions SVR to previous IFN treatment before the development of HCV-related HCC was associated with lower risk of the second recurrence of HCC and better survival.",
keywords = "Hepatitis C virus, Hepatocellular carcinoma, Previous interferon therapy, Recurrence, Survival",
author = "Hirokazu Miyatake and Yoshiyuki Kobayashi and Yoshiaki Iwasaki and Nakamura, {Shin Ichiro} and Hideki Ohnishi and Kenji Kuwaki and Junichi Toshimori and Hiroaki Hagihara and Kazuhiro Nouso and Kazuhide Yamamoto",
year = "2012",
month = "4",
doi = "10.1007/s10620-011-1934-1",
language = "English",
volume = "57",
pages = "1092--1101",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma

AU - Miyatake, Hirokazu

AU - Kobayashi, Yoshiyuki

AU - Iwasaki, Yoshiaki

AU - Nakamura, Shin Ichiro

AU - Ohnishi, Hideki

AU - Kuwaki, Kenji

AU - Toshimori, Junichi

AU - Hagihara, Hiroaki

AU - Nouso, Kazuhiro

AU - Yamamoto, Kazuhide

PY - 2012/4

Y1 - 2012/4

N2 - Background and Aims Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) prevents the development of hepatocellular carcinoma (HCC). The purpose of this study was to clarify the effect of previous IFN treatment before the development of HCC on recurrence and survival in HCV-related HCC patients. Methods Three hundred ninety-five patients who underwent curative treatment for HCV-related HCC were enrolled. Of these, 124 hadReceived IFN treatment before the development of HCC (17 achieved sustained virological response [SVR group] and 107 did not [non-SVR group]), whereas 271 patients had never Received IFN treatment (IFN-untreated group). The first and second recurrence and survival rates in these patient groups were statistically analyzed. Results The first HCC recurrence rate was similar among patient groups. In contrast, the second HCC recurrence rate was significantly lower in the SVR group than in the non- SVR group (p = 0.003) and the IFN-untreated group (p = 0.006). In multivariate analysis, platelet count (p = 0.033) and number of tumors (p = 0.001) were associated with the first HCC recurrence, while SVR (p = 0.002) was the only factor associated with the second HCC recurrence. The survival rate was higher in the SVR group than in non-SVR and IFN-untreated groups, and SVR to previous IFN treatment was an independent factor associated with better survival (p\0.001). Conclusions SVR to previous IFN treatment before the development of HCV-related HCC was associated with lower risk of the second recurrence of HCC and better survival.

AB - Background and Aims Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) prevents the development of hepatocellular carcinoma (HCC). The purpose of this study was to clarify the effect of previous IFN treatment before the development of HCC on recurrence and survival in HCV-related HCC patients. Methods Three hundred ninety-five patients who underwent curative treatment for HCV-related HCC were enrolled. Of these, 124 hadReceived IFN treatment before the development of HCC (17 achieved sustained virological response [SVR group] and 107 did not [non-SVR group]), whereas 271 patients had never Received IFN treatment (IFN-untreated group). The first and second recurrence and survival rates in these patient groups were statistically analyzed. Results The first HCC recurrence rate was similar among patient groups. In contrast, the second HCC recurrence rate was significantly lower in the SVR group than in the non- SVR group (p = 0.003) and the IFN-untreated group (p = 0.006). In multivariate analysis, platelet count (p = 0.033) and number of tumors (p = 0.001) were associated with the first HCC recurrence, while SVR (p = 0.002) was the only factor associated with the second HCC recurrence. The survival rate was higher in the SVR group than in non-SVR and IFN-untreated groups, and SVR to previous IFN treatment was an independent factor associated with better survival (p\0.001). Conclusions SVR to previous IFN treatment before the development of HCV-related HCC was associated with lower risk of the second recurrence of HCC and better survival.

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Previous interferon therapy

KW - Recurrence

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84864063993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864063993&partnerID=8YFLogxK

U2 - 10.1007/s10620-011-1934-1

DO - 10.1007/s10620-011-1934-1

M3 - Article

VL - 57

SP - 1092

EP - 1101

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 4

ER -